An Overview of Secondary Prevention Implantable Cardioverter-Defibrillator Trials: AVID, CIDS and CASH

  • G. V. Naccarelli
  • D. L. Wolbrette
  • H. T. Patel
  • J. Dell’Orfano
  • J. C. Luck
Conference paper


Sudden cardiac death, usually due to a ventricular tachyarrhythmia, accounts for 350,000–400,000 deaths annually in the United States. Less than 20% of patients will survive a cardiac arrest and be discharged alive from a hospital [1]. Of the survivors, 50% will be dead within 3 years [1]. Since survivors of a cardiac arrest are at high risk for a recurrent arrhythmic event, aggressive management of this group of patients is mandatory. Unfortunately, patients with previous sustained ventricular tachyarrhythmias only account for < 1% of patients who die suddenly. Given the high subsequent event rate and the low chance of surviving another cardiac arrest, there has been aggressive prescription of antiarrhythmic drugs, in an attempt to prevent arrhythmia recurrence, and of implantable cardioverterdefibrillators (ICDs), to successfully convert a sustained ventricular tachyarrhythmia [2]. Previous trials have suggested that amiodarone and sotalol are the most effective antiarrhythmic agents in patients with sustained ventricular tachycardia (VT)/ventricular fibrillation (VF). Antiarrhythmic approaches in these trials have included empirical and Holter/electrophysiologically guided use of these antiarrhythmic drugs [3]. One study of cardiac arrest survivors demonstrated that class I agents had a deleterious effect on survival [4]. In the same study [4], β-blockers improved survival. The benefits of β-blockers are supported by their known effects in prolonging survival in high-risk patients post-myocardial infarction (MI) or with congestive heart failure (CHF) [5].


Antiarrhythmic Drug Implantable Defibrillator Cardiac Arrest Survivor Antiarrhythmic Versus Implantable Defibrillator Canadian Implantable Defibrillator Study 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schaffer WA, Cobb LA (1975) Recurrent ventricular fibrillation as mode of death in survivors of out-of-hospital ventricular fibrillation. N Engl J Med 293:259–262PubMedCrossRefGoogle Scholar
  2. 2.
    Gilman JK, Jalal S, Naccarelli GV (1994) Predicting and preventing sudden death from cardiac causes. Circulation 90:1083–1092PubMedCrossRefGoogle Scholar
  3. 3.
    Mason JW, the ESVEM Investigators (1993) A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic drug efficacy for ventricular tachyarrhythmias. N Engl J Med 329:445–451PubMedCrossRefGoogle Scholar
  4. 4.
    Hallstrom AP, Cobb LA,Yu BH, Weaver WD, Fahrenbruch CE (1991) An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970–1985. Am J Cardiol 68:1025–1031PubMedCrossRefGoogle Scholar
  5. 5.
    Naccarelli GV, Wolbrette DL, Dell’Orfano JT, Patel HM, Luck JC (1998) A decade of clinical trial developments in postmyocardial infarction, congestive heart failure, and sustained ventricular tachyarrhythmia patients: from CAST to AVID and beyond. J Cardiovasc Electrophysiol 9:864–891PubMedCrossRefGoogle Scholar
  6. 6.
    Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R, for the Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) (1994) Randomized trial of low-dose amiodarone in severe congestive heart failure: Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 344:493–498PubMedCrossRefGoogle Scholar
  7. 7.
    Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D, for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure (1995) Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 333:77–82PubMedCrossRefGoogle Scholar
  8. 8.
    Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P, for the European Myocardial Infarct Amiodarone Trial Investigators (1997) Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 349:667–674PubMedCrossRefGoogle Scholar
  9. 9.
    Cairns JA, Connolly SJ, Roberts R, Gent M, for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators (1997) Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 349:675–682PubMedCrossRefGoogle Scholar
  10. 10.
    Sim I, McDonald KM, Lavori PW, Norbutas CM, Hlatky MA (1997) Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation 96:2823–2829PubMedCrossRefGoogle Scholar
  11. 11.
    Amiodarone Trials Meta-Analysis Investigators (1997) Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet 350:1417–1424CrossRefGoogle Scholar
  12. 12.
    Weinberg BA, Miles WM, Klein LS, Bolander JE, Dusman RE, Stanton MS, Heger JJ, Langefìeld C, Zipes DP (1993) Five-year follow-up of 589 patients treated with amiodarone. Am Heart J 125:109–120PubMedCrossRefGoogle Scholar
  13. 13.
    Herre J, Sauve M, Malone P, Griffin J, Helmy I, Langberg J, Goldberg H, Scheinman M (1989) Long-term results of amiodarone therapy with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 13:442–449PubMedCrossRefGoogle Scholar
  14. 14.
    The CASCADE Investigators (1993) Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am J Cardiol 72:280–287CrossRefGoogle Scholar
  15. 15.
    Mason JW, the ESVEM Investigators (1993) A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 329:445–451PubMedCrossRefGoogle Scholar
  16. 16.
    Julian DG, Prescott RJ, Jackson FS, Szekeley P (1982) Controlled trial of sotalol for one year after myocardial infarction. Lancet 1:1142–1147PubMedCrossRefGoogle Scholar
  17. 17.
    Winkle R, Mead H, Ruder M, Gaudiani V, Smith N, Buch W, Schmidt P, Shipman T (1989) Long-term outcome with the automatic implantable cardioverter defibrillator. J Am Coll Cardiol 13:1353–1361PubMedCrossRefGoogle Scholar
  18. 18.
    Lehmann MH, Steinman RT, Schuger CD, Jackson K (1988) The automatic cardioverter defibrillator as antiarrhythmic treatment modality of choice for survivors of cardiac arrest unrelated to acute myocardial infarction. Am J Cardiol 62:803–805PubMedCrossRefGoogle Scholar
  19. 19.
    Nisam S (1998) Can Implantable defìbrillators reduce non-arrhythmic mortality? J Interventional Cardiac Electrophysiol 2:371–375CrossRefGoogle Scholar
  20. 20.
    Estes M (1996) Clinical strategies for use of the implantable cardioverter-defibrillator: the impact of current trials. PACE 19:1011–1015PubMedCrossRefGoogle Scholar
  21. 21.
    Newman D, Sauve J, Herre J, Langberg J, Lee M, Titus C, Scheinman M (1992) Survival after implantation of the cardioverter-defibrillator. Am J Cardiol 69:889–903CrossRefGoogle Scholar
  22. 22.
    Wever EFD, Hauer RNW, van Capelle FJL, Tijssen JGP, Crijns HJGM, Algra A, Wiesfeld ACP, Bakker PFA, Robles de Medina EO (1995) Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation 91:2195–2203PubMedCrossRefGoogle Scholar
  23. 23.
    The Antiarrhythmics versus Implantable Defìbrillators (AVID) Investigators (1997) A comparison of antiarrhythmic-drug therapy with implantable defìbrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 337:1576–1583CrossRefGoogle Scholar
  24. 24.
    Siebels J, Cappato R, Ruppel R, Schneider MAE, Kuck KH, and the CASH Investigators (1993) Preliminary Results of the Cardiac Arrest Study Hamburg (CASH). Am J Cardiol 72:FIO9–FH3CrossRefGoogle Scholar
  25. 25.
    Kuck KH, for the CASH Investigators (1998) Cardiac Arrest Study Hamburg (CASH). Presented at the 47th Annual Scientific Sessions of the American College of Cardiology. Late Breaking Clinical Trials IGoogle Scholar
  26. 26.
    Connolly S, Gent M, Roberts RS, Dorian P, Green MS, Klein GJ, Mitchell LB, Sheldon RS, Roy D (1993) Canadian Implantable Defibrillator Study (CIDS): Study design and organization. Am J Cardiol 72:F103–F108CrossRefGoogle Scholar
  27. 27.
    Connolly SJ, for the CIDS Investigators (1998) Canadian Implantable Defìbrillator Study. Presented at the 47th Annual Scientific Sessions of the American College of Cardiology. Late Breaking Clinical Trials IGoogle Scholar
  28. 28.
    Curtis AB, Hallstrom AF, Klein RC, Nath S, Pinski SL, Epstein AE, Wyse DG, Cannom DS, Renfroe E, for the AVID Investigators (1997) Influence of patient characteristics in the selection of patients for defìbrillator implantation (the AVID Registry). Am J Cardiol 79:1185–1189PubMedCrossRefGoogle Scholar
  29. 29.
    Kim SG, Hallstrom A, Love JC, Rosenberg Y, Powell J, Roth J, Brodsky M, Moore R, Wükoff B, for the AVID Investigators (1997) Comparison of clinical characteristics and frequency of implantable defibrillator use between randomized patients in the Antiarrhythmics versus Implantable Defìbrillators (AVID) trial and nonrandomized registry patients. Am J Cardiol 80:454–457PubMedCrossRefGoogle Scholar
  30. 30.
    Anderson JL, HaUstrom AP, Epstein AE, Pinski SL, Rosenberg Y, Nora MO, Chilson D, Cannom DS, Moore R, and the AVID Investigators (1999) Design and results of the antiarrhythmic vs implantable defibrillators (AVID) registry. Circulation 99:1692–1699PubMedCrossRefGoogle Scholar
  31. 31.
    Cappato R (1999) Secondary prevention of sudden death: the Dutch study, the Antiarrhythmics versus Implantable Defibrillator Trial, the Cardiac Arrest Study Hamburg, and the Canadian Implantable Defibrillator Study. Am J Cardiol 83:D68–D73CrossRefGoogle Scholar
  32. 32.
    Myerburg RJ, Mitrani R, Interian A, Castellanos A (1998) Interpretation of outcomes of antiarrhythmic clinical trials. Design features and population impact. Circulation 97:1514–1521PubMedCrossRefGoogle Scholar
  33. 33.
    Larsen GC, McAnulty JH, Hallstrom A, Marchant C, Shein M, Akiyama Y, Brodsky M, Baessler C, Pinski S, Jennings CA, Morris M (1997) Hospitalization charges in the Antiarrhythmics versus Implantable Defibrillators (AVID) Trial: the AVID economic analysis study. Circulation 96:1–77 (abstr)Google Scholar
  34. 34.
    Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M, for the Multicenter Automatic Defibrillator Implantation Trial Investigators (1996) Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 335:1933–1940PubMedCrossRefGoogle Scholar
  35. 35.
    Mushlin AI, Hall WJ, Zwanziger J, Gajary E, Andrews M, Marron R, Zou KH, Moss AJ (1998) Cost-effectiveness of automatic implantable cardiac defìbrillators: results from MADIT. Circulation 97:2129–2135PubMedCrossRefGoogle Scholar
  36. 36.
    Gregoratos G, Cheitlin MD, Conill A, Epstein AE, Fellows C, Ferguson TB, Freedman RA, Hlatky MA, Naccarelli GV, Saksena S, Schlant RC, Silka MJ (1998) ACC/AHA Guidelines for implantation of cardiac pacemakers and antiarrhythmia devices. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). J Am Coll Cardiol 31:117–1209Google Scholar
  37. 37.
    Naccarelli GV, Dougherty AH, Wolbrette D (1995) Antiarrhythmic drug implantable cardioverter/defìbrillator interactions. In: Zipes DP, Jalife J (eds) From cell to bedside. WB Saunders, Philadelphia, pp 1426–1433Google Scholar
  38. 38.
    Holmes DR, Davis KB, Mock MB, Fisher LD, Gersch BJ, Killip T, Pettinger M, Participants in the Coronary Artery Surgery Study (1986) The effect of medical and surgical treatment on subsequent cardiac death in patients with coronary artery disease: a report from the Coronary Artery Surgical Study. Circulation 73:1254–1263PubMedCrossRefGoogle Scholar
  39. 39.
    Bigger JT, for the CABG Patch Trial Investigators (1997) Prophylactic use of implanted cardiac defìbrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery. N Engl J Med 337:1569–1575PubMedCrossRefGoogle Scholar
  40. 40.
    Nisam S, Mower M (1998) ICD trials: an extraordinary means of determining patient risk? PACE 21:1341–1346PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2000

Authors and Affiliations

  • G. V. Naccarelli
    • 1
  • D. L. Wolbrette
    • 1
  • H. T. Patel
    • 1
  • J. Dell’Orfano
    • 1
  • J. C. Luck
    • 1
  1. 1.Section of Cardiology and Cardiovascular CenterPenn State University College of MedicineHersheyUSA

Personalised recommendations